Table 1 Clinical characteristics of the RA patients’ group (N = 204)
From: The role of the Beclin-1: a gene related to autophagy in rheumatoid arthritis
Variable | Value |
|---|---|
Age (years) | |
Mean ± SD | 44.56 ± 11.3 |
Median, range | 45 (22–70) |
Disease duration | |
Mean ± SD | 7.9 ± 3.53 |
Median, range | 6 (1–30) |
Sex | |
Male, no % | 22 (10.87%) |
Female, no% | 184 (89.22%) |
Comorbidities: No % | |
• HTN | 70 (34.3%) |
• Diabetes | 30 (14.7%) |
• HCV | 8 (3.9%) |
• ILD | 8 (3.9%) |
• Ischemic heart | 6 (2.9%) |
• None | 82 (40.2%) |
Laboratory findings: | |
ESR | |
Mean ± SD | 28.07 ± 0 |
Median (range) | 30 (0–67) |
CRP | |
Mean ± SD | 8.32 ± 5.65 |
Median (range) | 8 (3–12) |
RF | |
Mean ± SD | 26.45 ± 1.41 |
Median (range) | 22 (5–52) |
Anti-CCP | |
Mean ± SD | 27.73 ± 18.38 |
Median (range) | 25 (10–60) |
Disease activity (DAS) | |
Mean ± SD | 4.37 ± 0. 66 |
Median, range | 4.33 (2.4–7.63) |
Grades: | |
• Remission: | 8 (3.9%) |
• Mild: | 29 (14.2%) |
• Moderate: | 89 (43.6%) |
• Severe: | 78 (38.2%) |
Patient global health | |
Mean ± SD | 5.34 ± 2.12 |
Median, range | 5 (1–10) |
Physician global health | |
Mean ± SD | 4.75 ± 1.41 |
Median, range | 5 (1–8) |
Morning stiffness (min) | |
Mean ± SD | 19.90 ± 3.53 |
Median, range | 15 (0–60) |
MHAQ | |
Mean ± SD | 0.98 ± 0.17 |
Median, range | 1 (0–2.5) |
MHAQ grade | |
• Normal | 15.7 (32%) |
• Mild | 54.9 (112%) |
• Moderate | 41 (20.1%) |
• Severe | 19 (9.3%) |
Treatments No % | |
HCQ | 180 (88.2%) |
MTX | 106 (52%) |
LEF | 88 (43.13%) |
SSZ | 77 (37.7%) |
AZA | 14 (6.86%) |
Steroids | 56 (27.5%) |
NSAIDS | 34 (16.6%) |